Caxton Associates LP bought a new position in Manhattan Associates, Inc. (NASDAQ:MANH – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,928 shares of the software maker’s stock, valued at approximately $791,000.
Several other hedge funds also recently made changes to their positions in the company. Twin Tree Management LP bought a new stake in Manhattan Associates in the 4th quarter worth $25,000. Whipplewood Advisors LLC purchased a new stake in shares of Manhattan Associates during the fourth quarter worth about $34,000. Synergy Asset Management LLC bought a new stake in shares of Manhattan Associates in the fourth quarter worth about $35,000. Transce3nd LLC purchased a new position in Manhattan Associates during the 4th quarter valued at about $41,000. Finally, Bank of Jackson Hole Trust bought a new position in Manhattan Associates during the 4th quarter valued at approximately $72,000. 98.45% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
MANH has been the topic of a number of research reports. DA Davidson lifted their target price on shares of Manhattan Associates from $195.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday, April 23rd. Citigroup decreased their target price on Manhattan Associates from $244.00 to $184.00 and set a “neutral” rating for the company in a research report on Friday, March 14th. William Blair upgraded Manhattan Associates from a “market perform” rating to an “outperform” rating in a research report on Thursday, February 13th. Truist Financial increased their price objective on Manhattan Associates from $180.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, April 23rd. Finally, Raymond James dropped their target price on shares of Manhattan Associates from $305.00 to $270.00 and set an “outperform” rating on the stock in a report on Wednesday, January 29th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Manhattan Associates presently has an average rating of “Moderate Buy” and a consensus target price of $212.38.
Manhattan Associates Trading Down 0.6 %
MANH opened at $182.83 on Wednesday. The company’s 50 day moving average is $169.14 and its 200 day moving average is $228.44. The company has a market cap of $11.10 billion, a price-to-earnings ratio of 52.09 and a beta of 1.13. Manhattan Associates, Inc. has a 12-month low of $140.81 and a 12-month high of $312.60.
Insider Transactions at Manhattan Associates
In other news, CFO Dennis B. Story sold 2,788 shares of Manhattan Associates stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $170.83, for a total transaction of $476,274.04. Following the transaction, the chief financial officer now directly owns 101,263 shares of the company’s stock, valued at $17,298,758.29. The trade was a 2.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.72% of the company’s stock.
Manhattan Associates Profile
Manhattan Associates, Inc develops, sells, deploys, services, and maintains software solutions to manage supply chains, inventory, and omni-channel operations. It offers Warehouse Management Solution for managing goods and information across the distribution centers; Manhattan Active Warehouse Management, a cloud native and version less application for the associate; and Transportation Management Solution for helping shippers navigate their way through the demands and meet customer service expectations at the lowest possible freight costs; Manhattan SCALE, a portfolio of logistics execution solution; and Manhattan Active Omni, which offers order management, store inventory and fulfillment, POS, and customer engagement tools for enterprises and stores.
See Also
- Five stocks we like better than Manhattan Associates
- Insider Trading – What You Need to Know
- 3 Mid-Cap Medical Stocks Outperforming the Market
- Using the MarketBeat Stock Split Calculator
- The Top-Ranked Insider Buys From April by Market Cap
- How to Capture the Benefits of Dividend Increases
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for Manhattan Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Manhattan Associates and related companies with MarketBeat.com's FREE daily email newsletter.